<code id='800566FA64'></code><style id='800566FA64'></style>
    • <acronym id='800566FA64'></acronym>
      <center id='800566FA64'><center id='800566FA64'><tfoot id='800566FA64'></tfoot></center><abbr id='800566FA64'><dir id='800566FA64'><tfoot id='800566FA64'></tfoot><noframes id='800566FA64'>

    • <optgroup id='800566FA64'><strike id='800566FA64'><sup id='800566FA64'></sup></strike><code id='800566FA64'></code></optgroup>
        1. <b id='800566FA64'><label id='800566FA64'><select id='800566FA64'><dt id='800566FA64'><span id='800566FA64'></span></dt></select></label></b><u id='800566FA64'></u>
          <i id='800566FA64'><strike id='800566FA64'><tt id='800566FA64'><pre id='800566FA64'></pre></tt></strike></i>

          
          WSS
          King Street Properties’ Pathway Devens campus. -- biotech coverage from STAT
          Pat Greenhouse/Globe Staff

          MORRISVILLE, N.C. — Ten minutes from the Raleigh airport, the future of biotech is under construction.

          On either side of a new stretch of four-lane highway sit two $1 billion biomanufacturing campuses, which will bring a combined 2.5 million square feet of research and development and advanced manufacturing space to a region that has become the No. 1 place where North America makes prescription drugs.

          advertisement

          One campus, called Pathway Triangle, is being built by a developer from Boston, King Street Properties. King Street — which has projects in Cambridge, Waltham, Allston, and Lexington — is building a similarly vast biomanufacturing campus in Devens. But these days it also sees a land of opportunity 700 miles to the south, in North Carolina.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          hotspot